Lugo D

Latest

• Generation of a selective small molecule inhibitor of the CBP/p300 bromodomain for leukemia therapy
• Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia
• Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia